Migraine Medications That Alleviate Headaches and Dizziness Symptoms

A medication called Ubrogepant, which is currently prescribed for migraine treatment, has been found to alleviate non-headache symptoms that often precede the onset of migraines. This makes it the first medication known to address these initial signs.

Before migraine headaches decrease in intensity, many individuals experience warning signs such as light sensitivity, sounds, dizziness, and neck stiffness, all of which can significantly disrupt daily activities.

Developers of migraine medications have predominantly concentrated on treating the headaches themselves, with no effective solutions available for alleviating these preliminary symptoms.

However, Ubrogepant demonstrated promising results when administered during the early stages of migraine symptoms, according to Peter Goadsby from King’s College London and his team, who are eager to further explore this potential.

Their study involved 438 participants, aged 18 to 75, all with a history of migraines. Half received a 100 mg dose of the medication upon experiencing suggestive symptoms of an impending migraine. The other half took a placebo during a subsequent episode of prodromal symptoms.

Following the administration of Ubrogepant, participants reported an enhanced ability to focus after 1 hour, decreased sensitivity to light after 2 hours, and reduced fatigue and neck discomfort after 3 hours, compared to their experiences while taking the placebo. They also noted less sensitivity to dizziness and sound when using Ubrogepant.

“Taking Ubrogepant allowed individuals to mitigate these non-pain symptoms even before the headache began,” Goadsby remarked.

This study did not delve into the impact of the medication on aura, another early feature of migraines that includes sensory disturbances like flashing lights or blind spots.

“The potential for intervention in the migraine progression is clinically significant given the often debilitating early symptoms,” remarked Parisa Gazerani from Oslo Metropolitan University, Norway. However, she emphasizes the need for further studies to ensure broad applicability.

“This research indicates that migraine treatments could lessen these preliminary symptoms and may prevent the progression to the main headache phase,” stated Rob Music, head of the Migraine Trust in the UK. “We are eager to see more investigations in this area to lessen the burden of migraines on daily living.”